[Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
D015250:Aclarubicin / Q000031:analogs & derivatives; D000208:Acute Disease; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D002360:Carubicin / Q000627:therapeutic use; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015251:Epirubicin; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D015255:Idarubicin; D007938:Leukemia / Q000188:drug therapy*; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; C011157:aclacinomycins; C016163:valrubicin; C015338:marcellomycin; D015251:Epirubicin; D015250:Aclarubicin; D004317:Doxorubicin; C017218:detorubicin; C027260:pirarubicin; D002360:Carubicin; D015255:Idarubicin; D003630:Daunorubicin
La terapia della leucemia acuta: contributo dei nuovi farmaci antracicilinici.